EUDA Health Launches Comprehensive Stem Cell Platform in China with National Clinical Network
核心洞察
EUDA Health Holdings Limited (搜索) has launched a nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China through partnerships with Shenzhen Inno Immune Co. and Wuhan Kaien Hospital (搜索).
The platform features centralized processing capabilities with Shenzhen Inno serving as the primary hub for 50,000 patient cell units and Wuhan Kaien Hospital (搜索) supporting up to 200,000 units.
EUDA has established its first longevity clinic in Shenzhen, offering advanced stem cell and T-cell immunotherapies (搜索), personalized AI-guided life cycle management, and integrated Eastern, Western, and functional medicine.
EUDA Health Holdings Limited (搜索) has announced the launch of a comprehensive nationwide stem cell platform in China, marking a significant expansion of the Singapore-based healthcare provider's regenerative medicine capabilities. The company has established strategic partnerships with Shenzhen Inno Immune Co., Ltd. (搜索) and Wuhan Kaien Hospital (搜索) to create an integrated system spanning cell extraction, processing, cryogenic storage, and clinical delivery across China.
National Infrastructure Development
The platform operates on three core design principles: centralized processing with decentralized access to ensure quality and compliance without limiting geographic reach, long-term cell preservation to enable patients to store biological material earlier in life for potential future clinical use, and integration with longevity medicine so that cell services are embedded within broader preventive, regenerative and personalized health programs.
Shenzhen Inno Immune Co., Ltd. (搜索) serves as EUDA's primary cell processing and cryogenic storage hub in Southern China, with an initial designed cryogenic storage capacity of approximately 50,000 patient cell units under controlled conditions. The company is upgrading Shenzhen Inno's cGMP facility to create a state-of-the-art production and innovation center for stem cell treatments.
Advanced Technology Integration
The enhanced cGMP facility incorporates GO POSB's proprietary induced pluripotent stem cell (搜索) (iPSC) technological platform with advanced stem cell technologies sourced from two Japanese partners, including Japan Early Light Medical Corporation (搜索). The facility will support iPSC expansion, stem cell preparation, immune cell therapies (搜索), and the development of new treatments focused on immune health, skin health, and healthy aging.
The company and its partners will explore cell-based solutions using iPSC technology, which converts human blood cells into stem cells capable of becoming nearly any cell type. This advancement positions EUDA to operate at the frontier of regenerative medicine with comprehensive end-to-end capabilities.
Clinical Network Expansion
Wuhan Kaien Hospital (搜索) serves as EUDA's Central China clinical and longevity flagship, with a planned cryogenic biostorage and clinical capacity designed to support up to approximately 200,000 patient cell units, integrated with inpatient, outpatient and long-term health management services. The hospital is positioned as a five-star, integrated anti-aging and preventive healthcare center that brings together regenerative medicine, non-drug chronic disease management, hormone and metabolic balance, immune support, early-warning diagnostics and personalized long-term health planning within one institutional setting.
Shenzhen Longevity Clinic Launch
In parallel with the infrastructure development, EUDA, in partnership with KB International Ltd. (搜索), has established a new longevity clinic in Shenzhen. This clinic is strategically positioned to be the first in the region to comprehensively introduce Japanese longevity healthcare technologies, offering advanced stem cell and T-cell immunotherapies (搜索) produced at the upgraded GMP facility in Shenzhen, personalized AI-guided life cycle management, and integrated Eastern, Western, and functional medicine.
The clinic focuses on enhancing longevity by slowing biological aging, strengthening immunity, and providing long-term health planning, supported by partnerships with leading longevity institutions and hospitals in Japan, the United States, and Singapore.
Strategic Vision
Alfred Lim, CEO of EUDA, stated: "This is a defining moment in EUDA's evolution. By combining an iPSC platform, expanding stem cell and t-cell therapies, the new upgraded GMP facility's production capacity, and a fully integrated longevity clinic, we are building a comprehensive, end-to-end regenerative ecosystem. Our robust partnerships with Shenzhen Inno, GO POSB, and the introduction of leading Japanese clinical expertise, positions EUDA to capitalize on the fast-growing longevity sector and operate at the frontier of healthcare."
The platform includes a nationwide clinical access layer via partner clinic networks enabling local extraction and downstream clinical delivery, creating a closed-loop, compliant operating system that enables patients to access stem cell services across a wide geographic footprint while maintaining centralized processing standards. EUDA aims to address the evolving healthcare needs of over 1.8 billion people across the region, which is experiencing significant demographic shifts as more than 30% of the population ages rapidly.